Patents by Inventor Bruce D. Weintraub
Bruce D. Weintraub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210054041Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: ApplicationFiled: September 4, 2020Publication date: February 25, 2021Applicant: Trophogen Inc.Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
-
Patent number: 10766941Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: GrantFiled: August 20, 2015Date of Patent: September 8, 2020Assignee: Trophogen Inc.Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
-
Patent number: 10544200Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: GrantFiled: November 5, 2014Date of Patent: January 28, 2020Assignee: TROPHOGEN, INC.Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
-
Patent number: 10457713Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: GrantFiled: August 29, 2018Date of Patent: October 29, 2019Assignee: TROPHOGEN, INC.Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
-
Publication number: 20190127432Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: ApplicationFiled: August 29, 2018Publication date: May 2, 2019Applicant: TROPHOGEN INC.Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
-
Publication number: 20170087214Abstract: Modified follicle stimulating hormone (FSH), containing an amino acid sequence which differs from the wild-type FSH, said modified FSH comprising a modified ?-subunit, wherein the potency of said modified FSH is increased by at least about a ten fold as compared to wild type FSH. Nucleic acids encoding the modified FSH, vectors comprising the nucleic acids, and host cells comprising the vectors. Methods of assisting reproduction, diagnosing and/or treating conditions associated with glycoprotein hormone activity, reducing hyperstimulation syndrome, improving the quality of oocytes, inducing superovulation, and enhancing in vitro fertilization.Type: ApplicationFiled: May 12, 2015Publication date: March 30, 2017Applicant: Trophogen, Inc.Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Publication number: 20160264639Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: ApplicationFiled: November 5, 2014Publication date: September 15, 2016Applicant: Trophogen Inc.Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
-
Publication number: 20160075751Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: ApplicationFiled: August 20, 2015Publication date: March 17, 2016Applicant: TROPHOGEN INC.Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
-
Patent number: 9249205Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: GrantFiled: June 19, 2014Date of Patent: February 2, 2016Assignee: TROPHOGEN, INC.Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
-
Patent number: 9187545Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: GrantFiled: July 30, 2013Date of Patent: November 17, 2015Assignee: Trophogen, Inc.Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
-
Publication number: 20150274793Abstract: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.Type: ApplicationFiled: June 12, 2015Publication date: October 1, 2015Applicant: Trophogen Inc.Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Patent number: 9078860Abstract: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.Type: GrantFiled: June 23, 2014Date of Patent: July 14, 2015Assignee: Trophogen, Inc.Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Publication number: 20140371146Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: ApplicationFiled: June 19, 2014Publication date: December 18, 2014Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Publication number: 20140308264Abstract: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.Type: ApplicationFiled: June 23, 2014Publication date: October 16, 2014Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Patent number: 8759285Abstract: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.Type: GrantFiled: October 6, 2006Date of Patent: June 24, 2014Assignee: Trophogen, Inc.Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Publication number: 20140031530Abstract: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: ApplicationFiled: July 30, 2013Publication date: January 30, 2014Applicant: Trophogen Inc.Inventors: Mariusz Szkudlinski, Bruce D. Weintraub
-
Publication number: 20140024589Abstract: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.Type: ApplicationFiled: February 19, 2013Publication date: January 23, 2014Applicant: TROPHOGEN, INC.Inventors: MARIUSZ W. SZKUDLINSKI, BRUCE D. WEINTRAUB
-
Patent number: 8377879Abstract: This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared to wild type protein. The analogs are particularly useful in treating subjects showing low FSH receptor expression or poor FSH receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: GrantFiled: July 21, 2011Date of Patent: February 19, 2013Assignee: Trophogen, Inc.Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Publication number: 20120035109Abstract: This invention provides superactive analogs of FSH demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type FSH. In particular, the analogs of the invention demonstrate at least a ten fold increase in potency or at least a ten percent increase in maximal efficacy as compared to wild type protein. The analogs are particularly useful in treating subjects showing low FSH receptor expression or poor FSH receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity.Type: ApplicationFiled: July 21, 2011Publication date: February 9, 2012Applicant: Trophogen, Inc.Inventors: Mariusz W. SZKUDLINSKI, Bruce D. Weintraub
-
Patent number: 8044187Abstract: The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the ?-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the ?-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone.Type: GrantFiled: May 15, 2009Date of Patent: October 25, 2011Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mariusz W. Szkudlinski, Bruce D. Weintraub, Mathis Grossmann